New Two-Drug attack on Tough-to-Treat leukemia
NCT ID NCT05441514
Summary
This early-stage trial is testing the safety and best dose of a combination of two oral drugs, enasidenib and cobimetinib, for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study is specifically for patients whose cancer has two particular types of genetic changes. The goal is to see if blocking two different cancer growth pathways at once can kill more cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.